Calculate reconstitution and exact units for retatrutide. One thing to state clearly up front: retatrutide is an investigational drug still in clinical trials. It is not approved anywhere, and its long term safety profile is not established.
Educational tool only. Not medical advice. Always verify doses independently before use.
Retatrutide is a triple agonist, acting on the GIP, GLP-1 and glucagon receptors. The glucagon component is what distinguishes it, contributing to increased energy expenditure alongside the appetite suppression the other two provide. Trial results have shown the largest average weight loss of any agent in this class so far — see how it stacks up against the Tirzepatide Dosage Calculator and the full GLP-1 Titration Calculator.
Impressive trial results are not the same as an established safety record. Retatrutide has not completed the full regulatory process, long term outcomes are not known, and anything sold outside a trial is unregulated with no guarantee of identity or purity. Titrating slowly is prudent, and this is a decision worth making with a physician rather than alone. Check The Peptide Database for the same evidence-graded honesty on every other compound.
No. It remains investigational and has not been approved by regulators. Any product available outside a clinical trial is unregulated, with no assurance of identity, purity or dosing accuracy.
As with other lyophilised peptides, add bacteriostatic water slowly down the vial wall and swirl gently. The water volume sets the concentration and therefore the units per dose.
Retatrutide adds glucagon receptor activity to the dual mechanism tirzepatide uses, and trials have reported greater average weight loss. It also has far less accumulated safety data, since tirzepatide is approved and retatrutide is not.
Predominantly gastrointestinal and dose dependent, similar in character to other drugs in the class, including nausea and vomiting. Because the drug is investigational, the complete picture is not yet established.
Trials used a gradual escalation over several weeks. Slower titration generally reduces gastrointestinal side effects with any drug in this class.
